

Heritage Pharma Labs Inc. Announces Acquisition of 23 FDA-Approved ANDAs

East Brunswick, NJ, February 6, 2019 – Heritage Pharma Labs Inc. (Heritage) today announced that they have acquired a portfolio of 23 abbreviated new drug applications (ANDAs), covering 17 product families, all of which have been previously approved by the U.S. Food and Drug Administration (FDA). Financial terms were not disclosed.

Of the newly acquired products, Heritage and its parent company, Emcure Pharmaceuticals Ltd. had previously manufactured most of these products under a supply agreement with a third party, and Heritage plans to launch all of these products into the U.S. market under a Heritage label with immediate availability starting in Q2 2019 through its affiliate, Heritage Pharmaceuticals Inc.

“The addition of these new products to our growing portfolio is another step forward in our efforts to strengthen our U.S. business and operations,” stated William S. Marth, the Global President and CEO of the Heritage Group, Regulated Markets. Mr. Marth added that “we remain focused on delivering high-quality products to our customers and patients. Our previous experience producing the vast majority of these products will enable us to quickly resume manufacturing and begin production immediately.”

About Heritage

A wholly owned subsidiary of Emcure Pharmaceuticals Limited, and strategically located in East Brunswick, New Jersey, Heritage Pharma Labs Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, packaging, and sales of generic and legacy branded pharmaceutical products for the U.S. prescription drug market. Since inception, our customers have experienced the benefits of our continuous product expansion and global alliance network among the Emcure and Heritage Group family that has produced an impressive portfolio of over 150 products spanning multiple dosage forms. The Heritage Group’s products cover several therapeutic categories, including but not limited to: oncology, cardiovascular, metabolic disease, anti-infective and pain management. Whether its oral solids or complex injectables, the Heritage portfolio is poised to continue to rapidly expand and deliver the Value Driven Medicine required to keep our customers competitive in the marketplace. Let our formula of high quality and consistent supply work for you as we continue to provide affordable healthcare solutions to the U.S. consumer.

###